Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Monday.
Several other research analysts have also recently weighed in on RARE. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Friday. JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 14th. Wedbush boosted their price target on shares of Ultragenyx Pharmaceutical from $71.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, August 6th. Canaccord Genuity cut their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 7th. Finally, Credit Suisse Group set a $59.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “hold” rating in a report on Thursday, November 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $75.95.
Ultragenyx Pharmaceutical stock traded up $2.23 during midday trading on Monday, hitting $55.51. 512,500 shares of the stock were exchanged, compared to its average volume of 534,587. Ultragenyx Pharmaceutical has a 52-week low of $41.67 and a 52-week high of $90.98. The stock has a market cap of $2.69 billion, a PE ratio of -7.40 and a beta of 2.34.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, topping the consensus estimate of ($1.94) by $0.20. Ultragenyx Pharmaceutical had a negative net margin of 508.70% and a negative return on equity of 40.10%. The business had revenue of $11.80 million for the quarter, compared to analysts’ expectations of $11.97 million. During the same period in the previous year, the company earned ($1.87) earnings per share. The firm’s revenue for the quarter was up 5800.0% compared to the same quarter last year. On average, equities analysts predict that Ultragenyx Pharmaceutical will post -3.99 EPS for the current fiscal year.
In other Ultragenyx Pharmaceutical news, Director William Aliski sold 6,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $55.67, for a total value of $334,020.00. Following the sale, the director now owns 72,610 shares of the company’s stock, valued at $4,042,198.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Shalini Sharp sold 6,700 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total transaction of $603,469.00. Following the completion of the sale, the chief financial officer now directly owns 56,828 shares in the company, valued at approximately $5,118,497.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,250 shares of company stock worth $2,354,669. Insiders own 8.40% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Advisors Asset Management Inc. bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth about $181,000. Pacer Advisors Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $222,000. Gideon Capital Advisors Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $303,000. Janney Montgomery Scott LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $313,000. Finally, Paloma Partners Management Co bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $343,000. 95.39% of the stock is currently owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Further Reading: Insider Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.